Aspect Biosystems yalengeza mgwirizano ndi JDRF, gulu lotsogola padziko lonse lapansi lofufuza za matenda a shuga 1 (T1D).
Mgwirizano wa JDRF-Aspect umathandizira kuti Aspect ayang'ane kwambiri pakupanga chithandizo chamankhwala opangidwa ndi bioengineered amtundu woyamba wa shuga womwe umapereka ufulu wodziyimira pawokha wa insulin komanso kuwongolera shuga wamagazi popanda kufunikira kwa kuponderezedwa kwa chitetezo chamthupi. Kuphatikiza pa ndalama, JDRF ikuperekanso thandizo laukadaulo kudzera muukadaulo wake wozama komanso maukonde ambiri pankhani ya matenda ashuga.
Aspect ikugwiritsa ntchito ukadaulo wake waukadaulo wa bioprinting, ma cell achirengedwe, ndi sayansi yazinthu kupanga mapaipi opangira ma cell omwe amalowa m'malo kapena kukonza ziwalo zomwe zawonongeka. Mankhwalawa amapangidwa mwanzeru kuti azigwira ntchito mwachilengedwe, ateteze chitetezo chamthupi, komanso oyenera kuyikidwa opaleshoni kuti athe kuchiza matenda monga mtundu woyamba wa shuga.
"Kwa zaka zoposa 20, JDRF yakhala ikutsogolera kafukufuku wamtundu wa matenda a shuga a mtundu wa 1," atero a Esther Latres, Wachiwiri Wachiwiri Wofufuza ku JDRF. "Mgwirizano wandalamawu ndi Aspect Biosystems uthandizira ndikupitiliza kupita patsogolo kwasayansi pantchitoyi ndipo mosakayikira utifikitsa pafupi ndikupeza chithandizo."
"Pamodzi ndi JDRF, tili ogwirizana ndi cholinga chopanga chithandizo chochizira odwala mamiliyoni ambiri padziko lonse lapansi omwe ali ndi matenda amtundu woyamba," atero a Tamer Mohamed, CEO ku Aspect Biosystems. "Mgwirizanowu utithandizira kupititsa patsogolo pulogalamu yathu yapang'onopang'ono komanso kutifikitsa pafupi ndi mayesero a anthu."
ZOMWE MUNGACHITE PA NKHANIYI:
- The JDRF-Aspect partnership supports Aspect’s focus on developing a bioengineered tissue therapeutic for type 1 diabetes that will provide insulin independence and control of blood sugar without the need for chronic immune suppression.
- “Together with JDRF, we are aligned on the mission to develop a curative therapy for the millions of patients around the world who are affected by type 1 diabetes,”.
- “This funding partnership with Aspect Biosystems will support and continue scientific advancements in the field and undeniably take us closer to finding a cure.
